Discussing Biosimilars With Patients

In the twelfth and final episode of the GHAPP & RhAPP biosimilar podcast series, host Gabriella McCarty, NP, sits down with Jamie Brogan, NP, for an essential discussion on how to effectively communicate with patients about biosimilars. As biosimilars continue to reshape treatment options in gastroenterology and rheumatology, advanced practice providers must be prepared to educate patients, address concerns, and foster confidence in these therapies.Throughout the conversation, Gabriella and Jamie explore the challenges of discussing biosimilars with patients and the best methods to explain their role in treatment. They dive into common misconceptions, including patient hesitancy about switching from reference biologics, and examine how to navigate these conversations with clarity and empathy. A key focus of the discussion is the nocebo effect—how negative patient expectations can influence treatment outcomes—and they share strategies to counteract these concerns through effective counseling and reassurance.Beyond addressing patient apprehensions, the episode highlights the many benefits of biosimilars, including improved accessibility, affordability, and the potential for broader treatment options. By fostering open and informed conversations, APPs can ensure that patients feel confident in their treatment decisions and embrace biosimilars as a viable and effective option.This final episode is a must-listen for healthcare providers looking to strengthen their approach to biosimilar discussions and enhance patient trust in these evolving therapies.Visit the RhAPP website or explore additional educational content on the RhAPP ACE App.Please take our evaluation regarding this podcast here:   https://www.rhapp.org/bio-podcast-eval